Burundi

Burundi

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
2.14 (2.07 - 2.20) 2019 Modelled IHME
2.27 (2.21 - 2.33) 2018 Modelled IHME
2.37 (2.30 - 2.44) 2017 Modelled IHME
2.43 (2.36 - 2.50) 2016 Modelled IHME
2.49 (2.41 - 2.57) 2015 Modelled IHME
2.58 (2.50 - 2.65) 2014 Modelled IHME
2.68 (2.60 - 2.76) 2013 Modelled IHME
2.8 (2.70 - 2.88) 2012 Modelled IHME
2.91 (2.81 - 3) 2011 Modelled IHME
3.03 (2.91 - 3.14) 2010 Modelled IHME
3.15 (3.03 - 3.26) 2009 Modelled IHME
3.28 (3.15 - 3.40) 2008 Modelled IHME
3.42 (3.27 - 3.54) 2007 Modelled IHME
3.53 (3.37 - 3.67) 2006 Modelled IHME
3.63 (3.45 - 3.79) 2005 Modelled IHME
3.72 (3.53 - 3.88) 2004 Modelled IHME
3.8 (3.60 - 3.98) 2003 Modelled IHME
3.88 (3.67 - 4.06) 2002 Modelled IHME
3.93 (3.72 - 4.13) 2001 Modelled IHME
3.95 (3.72 - 4.15) 2000 Modelled IHME
3.95 (3.73 - 4.14) 1999 Modelled IHME
3.94 (3.73 - 4.12) 1998 Modelled IHME
3.93 (3.72 - 4.12) 1997 Modelled IHME
3.93 (3.70 - 4.13) 1996 Modelled IHME
3.93 (3.69 - 4.13) 1995 Modelled IHME
3.93 (3.70 - 4.13) 1994 Modelled IHME
3.93 (3.70 - 4.13) 1993 Modelled IHME
3.94 (3.71 - 4.13) 1992 Modelled IHME
3.96 (3.74 - 4.15) 1991 Modelled IHME
3.97 (3.75 - 4.17) 1990 Modelled IHME
6.37 (3.87 - 10) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.18 (0.15 - 0.22) 2019 Modelled IHME
0.19 (0.16 - 0.23) 2018 Modelled IHME
0.2 (0.16 - 0.23) 2017 Modelled IHME
0.19 (0.16 - 0.23) 2016 Modelled IHME
0.19 (0.16 - 0.23) 2015 Modelled IHME
0.19 (0.16 - 0.23) 2014 Modelled IHME
0.19 (0.16 - 0.23) 2013 Modelled IHME
0.2 (0.16 - 0.23) 2012 Modelled IHME
0.2 (0.16 - 0.24) 2011 Modelled IHME
0.21 (0.17 - 0.25) 2010 Modelled IHME
0.25 (0.20 - 0.29) 2009 Modelled IHME
0.35 (0.28 - 0.42) 2008 Modelled IHME
0.5 (0.40 - 0.60) 2007 Modelled IHME
0.68 (0.54 - 0.81) 2006 Modelled IHME
0.87 (0.69 - 1.04) 2005 Modelled IHME
1.15 (0.93 - 1.36) 2004 Modelled IHME
1.55 (1.26 - 1.83) 2003 Modelled IHME
1.97 (1.61 - 2.32) 2002 Modelled IHME
2.3 (1.88 - 2.71) 2001 Modelled IHME
2.44 (1.97 - 2.88) 2000 Modelled IHME
2.44 (1.98 - 2.89) 1999 Modelled IHME
2.44 (1.97 - 2.89) 1998 Modelled IHME
2.43 (1.96 - 2.88) 1997 Modelled IHME
2.43 (1.94 - 2.89) 1996 Modelled IHME
2.43 (1.93 - 2.92) 1995 Modelled IHME
2.43 (1.94 - 2.92) 1994 Modelled IHME
2.44 (1.96 - 2.90) 1993 Modelled IHME
2.45 (1.97 - 2.92) 1992 Modelled IHME
2.46 (1.98 - 2.93) 1991 Modelled IHME
2.47 (1.98 - 2.96) 1990 Modelled IHME
2.59 (1.42 - 4.55) 2015 Modelled WHO
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
29 (22 - 38) 2019 Modelled IHME
29 (22 - 38) 2018 Modelled IHME
29 (22 - 38) 2017 Modelled IHME
29 (22 - 38) 2016 Modelled IHME
29 (22 - 38) 2015 Modelled IHME
29 (23 - 38) 2014 Modelled IHME
30 (23 - 38) 2013 Modelled IHME
30 (23 - 38) 2012 Modelled IHME
30 (23 - 38) 2011 Modelled IHME
30 (23 - 38) 2010 Modelled IHME
30 (23 - 38) 2009 Modelled IHME
30 (23 - 38) 2008 Modelled IHME
30 (23 - 38) 2007 Modelled IHME
29 (23 - 38) 2006 Modelled IHME
29 (22 - 38) 2005 Modelled IHME
29 (23 - 37) 2004 Modelled IHME
29 (22 - 38) 2003 Modelled IHME
29 (22 - 38) 2002 Modelled IHME
29 (22 - 38) 2001 Modelled IHME
29 (22 - 38) 2000 Modelled IHME
29 (22 - 37) 1999 Modelled IHME
29 (22 - 37) 1998 Modelled IHME
29 (22 - 37) 1997 Modelled IHME
28 (22 - 37) 1996 Modelled IHME
28 (22 - 37) 1995 Modelled IHME
28 (22 - 37) 1994 Modelled IHME
28 (21 - 37) 1993 Modelled IHME
28 (21 - 36) 1992 Modelled IHME
27 (21 - 36) 1991 Modelled IHME
27 (21 - 35) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
90 2018 Survey/reported WHO/UNICEF
91 2017 Survey/reported WHO/UNICEF
94 2016 Survey/reported WHO/UNICEF
94 2015 Survey/reported WHO/UNICEF
95 2014 Survey/reported WHO/UNICEF
96 2013 Survey/reported WHO/UNICEF
96 2012 Survey/reported WHO/UNICEF
96 2011 Survey/reported WHO/UNICEF
96 2010 Survey/reported WHO/UNICEF
94 2009 Survey/reported WHO/UNICEF
92 2008 Survey/reported WHO/UNICEF
99 2007 Survey/reported WHO/UNICEF
92 2006 Survey/reported WHO/UNICEF
87 2005 Survey/reported WHO/UNICEF
83 2004 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
0 (0 - 0) 2016 Survey/reported Harm Reduction International, 2016

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV National Action Plan
HBV elimination goal
Year of HBV elimination goal
2030
HBV testing policy
Pregnant women, Risk-based
HepB birth dose policy
Yes
Year of birth dose introduction
2016
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2030
HCV testing policy
Risk-based
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
2.69 (2.15 - 3.40) 2019 Modelled IHME
2.7 (2.15 - 3.45) 2018 Modelled IHME
2.7 (2.14 - 3.47) 2017 Modelled IHME
2.69 (2.14 - 3.39) 2016 Modelled IHME
2.68 (2.13 - 3.36) 2015 Modelled IHME
2.69 (2.14 - 3.39) 2014 Modelled IHME
2.72 (2.18 - 3.42) 2013 Modelled IHME
2.75 (2.21 - 3.48) 2012 Modelled IHME
2.79 (2.23 - 3.51) 2011 Modelled IHME
2.82 (2.24 - 3.58) 2010 Modelled IHME
2.85 (2.27 - 3.61) 2009 Modelled IHME
2.88 (2.30 - 3.63) 2008 Modelled IHME
2.91 (2.32 - 3.67) 2007 Modelled IHME
2.93 (2.34 - 3.72) 2006 Modelled IHME
2.96 (2.36 - 3.75) 2005 Modelled IHME
3 (2.39 - 3.78) 2004 Modelled IHME
3.03 (2.42 - 3.83) 2003 Modelled IHME
3.06 (2.44 - 3.89) 2002 Modelled IHME
3.09 (2.46 - 3.91) 2001 Modelled IHME
3.11 (2.47 - 3.91) 2000 Modelled IHME
3.12 (2.49 - 3.94) 1999 Modelled IHME
3.13 (2.50 - 3.95) 1998 Modelled IHME
3.13 (2.49 - 3.96) 1997 Modelled IHME
3.14 (2.50 - 3.95) 1996 Modelled IHME
3.15 (2.51 - 3.96) 1995 Modelled IHME
3.22 (2.60 - 4.01) 1994 Modelled IHME
3.4 (2.72 - 4.20) 1993 Modelled IHME
3.65 (2.94 - 4.46) 1992 Modelled IHME
3.95 (3.19 - 4.80) 1991 Modelled IHME
4.28 (3.42 - 5.20) 1990 Modelled IHME
1 (0.80 - 4) 2015 Modelled Blach et al, 2017
Showing out of
Show more

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
21 (14 - 28) 2019 Modelled IHME
21 (14 - 28) 2018 Modelled IHME
21 (15 - 28) 2017 Modelled IHME
20 (14 - 28) 2016 Modelled IHME
20 (14 - 27) 2015 Modelled IHME
20 (14 - 27) 2014 Modelled IHME
20 (14 - 27) 2013 Modelled IHME
20 (14 - 27) 2012 Modelled IHME
20 (14 - 27) 2011 Modelled IHME
20 (14 - 27) 2010 Modelled IHME
20 (14 - 27) 2009 Modelled IHME
20 (14 - 27) 2008 Modelled IHME
20 (14 - 27) 2007 Modelled IHME
20 (14 - 27) 2006 Modelled IHME
20 (14 - 27) 2005 Modelled IHME
20 (14 - 27) 2004 Modelled IHME
20 (14 - 27) 2003 Modelled IHME
20 (14 - 26) 2002 Modelled IHME
20 (14 - 27) 2001 Modelled IHME
20 (14 - 26) 2000 Modelled IHME
20 (14 - 26) 1999 Modelled IHME
20 (14 - 26) 1998 Modelled IHME
20 (14 - 26) 1997 Modelled IHME
20 (14 - 26) 1996 Modelled IHME
20 (14 - 26) 1995 Modelled IHME
19 (14 - 26) 1994 Modelled IHME
19 (14 - 26) 1993 Modelled IHME
19 (13 - 26) 1992 Modelled IHME
19 (13 - 26) 1991 Modelled IHME
19 (13 - 26) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 (0 - 0) 2016 Survey/reported Harm Reduction International, 2016

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV National Action Plan
HBV elimination goal
Year of HBV elimination goal
2030
HBV testing policy
Pregnant women, Risk-based
HepB birth dose policy
Yes
Year of birth dose introduction
2016
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2030
HCV testing policy
Risk-based
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No

Overview

HBV elimination goal
Year of goal
2030
HCV elimination goal
Year of goal
2030

Prevalence (national)

Modelled

HBV (HBsAg+)
2.14 (%)
2019
(2.07 - 2.2(%))
IHME
HCV (RNA/cAg+)
2.69 (%)
2019
(2.15 - 3.4(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
358
2019
(201 - 632)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
743
2019
(442 - 1,238)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.18 (%)
2019, latest modelled
(0.15 - 0.22(%))
IHME

Prevalence PWID

No data available

Birth dose vaccination coverage (national)

Survey/surveillance

No data available

No. of syringes/PWID/year

Survey/surveillance

HCV
0
2016
(0 - 0)
Harm Reduction International, 2016
Eligible for HBV generic medicines
Eligible for HCV generic medicines